Back to Studies

P1108

A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease

Study Status

Enrolling

DAIDS Number

11884

IND Number

131,832

Clinical Trials Link

Summary

P1108 is a Phase I/II, open-label, single-arm, exposure-controlled dose finding modified age de-escalation study of Bedaquiline (BDQ) in HIV-infected and HIV-uninfected pediatric populations with clinically diagnosed or confirmed intra-thoracic multidrug-resistant tuberculosis (MDR-TB). The study is designed to evaluate the pharmacokinetics, safety and tolerability of BDQ over 24 weeks from the initiation of study treatment.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...